Dafraclav suspension 457 mg

Form: Suspension
Dosage: 457mg
Packaging: Powder for oral suspension 70 ml

Active substance: amoxicillin – clavulanic acid

Form: powder for oral suspension


Ticasse / Dafraclav 228: 200 mg amoxicillin and 28.5 mg clavulanic acid per 5 ml suspension

Ticasse / Dafraclav 457: 400 mg amoxicillin and 57 mg clavulanic acid per 5 ml suspension



– Bottle with powder for the preparation of 70 ml of oral suspension



Ticasse / Dafraclav 228: children up to 2 years (12kg)

Ticasse / Dafraclav 457: children from 2 to 6 years (12 to 30 kg)

Ticasse / Dafraclav suspension is a bactericidal antibiotic

– Amoxicillin rapidly kills susceptible bacteria

– Clavulanic acid prevents the inactivation of amoxicillin by enzymes produced by bacteria.

Ticasse/Dafraclav is indicated for the treatment of the following infections

  • Infections of the upper respiratory tract
    • Otitis media / sinusitis / tonsillitis / pharyngitis / laryngitis
  • Infections of the lower respiratory tract
    • Chronic bronchitis (superinfection), community acquired pneumonia
  • Skin and soft tissue infections
    • Cellulitis, animal bites
    • Dental abscesses
    • Abscesses, boils, wounds, acnes superinfections
  • Urinary tract infections
    • Cystitis, pyelonephritis
  • Bone and joint infections

Suspensions 200/28 and 400/57 per 5 ml: The usual dose is 25 mg to 45 mg of amoxicillin body weight per day.

The higher dose is up to 70 mg amoxicillin body weight per day.

The daily dose should be divided into two equal portions, administered every 12 hours.

Use the measuring spoon provided to give the appropriate dose.


Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma